Marlise R. Luskin

2 months ago | healio.com | Marlise R. Luskin |Marley Ghizzone |Cory Perla |Mindy Valcarcel

SAN DIEGO — Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial. The study was put on hold due to grade 5 events among patients who received inotuzumab (Besponsa, Pfizer) and progressed onto chemotherapy, according to the abstract.

2 months ago | onlinelibrary.wiley.com | Evan Chen |Shai Shimony |Marlise R. Luskin |Richard Stone

Conflicts of Interest The authors declare no conflicts of interest. References 1, , , et al., “NPM1 Alternative Transcripts Are Upregulated in Acute Myeloid and Lymphoblastic Leukemia and Their Expression Level Affects Patient Outcome,” Journal of Translational Medicine 16, no. 1 (2018): 232. 2, , , and , “Acute Myeloid Leukemia Carrying Cytoplasmic/Mutated Nucleophosmin (NPMc+ AML): Biologic and Clinical Features,” Blood 109, no. 3 (2007): 874–885.

2 months ago | healio.com | Marlise R. Luskin |Marley Ghizzone |Cory Perla |Mindy Valcarcel

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.

Jul 20, 2024 | nature.com | Johann-Christoph Jann |Benjamin S. Braun |Shai Shimony |Richard Stone |Daniel DeAngelo |Jacqueline Garcia | +1 more

AbstractMutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit mutations share clinical characteristics and prognostic significance is not known.

Mar 27, 2024 | nature.com | Shai Shimony |Jacqueline Garcia |Marlise R. Luskin |Donna S. Neuberg |Daniel DeAngelo |Richard Stone

AbstractThe clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have differential benefit of venetoclax (VEN) added to hypomethylating agents (HMA). In secondary ontogeny (n = 115), median overall survival (OS)(14.1 vs. 6.9 months, P = 0.0054), composite complete remission (cCR 61% vs.